). In contrast, the anti-tumor response in Ythdf1 −/− mice was completely abrogated in the absence of CD8 + T cells (Fig. 1e, Extended Data Fig. 2i ), indicating that CD8 + T cells are essential for tumor control in the Ythdf1-deficient host.
To determine whether neoantigen-specific CD8 + T cell responses are generated in B16-OVA tumors, we analyzed the frequency of tumor-infiltrating SIINFEKL MHC-I tetramer + CD8 + T cells in WT and Ythdf1 −/− mice. While WT mice failed to accumulate antigen-specific CD8 + T cells within the tumor, Ythdf1 −/− showed a substantially increased CD8 + T cells against tumor neoantigen in vivo relative to WT mice (Fig. 2a, b) . To investigate whether the infiltration of neoantigen-specific CD8 + T cells in Ythdf1 −/− mice is due to enhanced spontaneous CD8 + T cell priming at an early stage, we stimulated lymphocytes from tumordraining lymph node in vitro, with or without the OVA-derived SIINFEKL peptide or tumor cells, and measured endogenous CD8 + T-cell responses using IFN-γ ELISPOT. Significantly more IFN-γ spot-forming cells were present in Ythdf1 −/− mice than in WT mice in both B16-OVA and MC38 tumor models (Fig. 2c, d ), indicating that YTHDF1 depletion in host cells potentiates the early steps of T-cell priming against tumor neoantigens.
Next, we showed that loss of Ythdf1 in T cells makes a minor contribution to the observed antitumor immunity (Extended Data Fig. 3a ). Since dendritic cells (DCs) are the main antigen-presenting cells (APCs) that cross-prime CD8 + T cells, we hypothesized that the increased T cell priming in Ythdf1 −/− mice could be attributed to an improved recognition of tumor cells through an increased cross-priming ability of DCs 18, 19 . To test this hypothesis, we used Flt3L-supplemented cultures for classical DCs (Flt3L-DC) to model how crosspresentation occurs [20] [21] [22] . We pulsed Flt3L-DCs with necrotic B16-OVA in vitro and evaluated their ability to cross-prime OTI-specific TCR-transgenic OT-I T cells. We found that Ythdf1 −/− Flt3L-DCs were able to cross-prime OT-I T cells to a greater extent than WT DCs (Fig. 2e) . To determine the cross-priming capacity of classical DCs (cDC) in vivo, we collected CD8α + DCs and CD11b + DCs from draining lymph nodes (DLNs) of B16-OVAor MC38-OTIp-tumor bearing mice and co-cultured them with OT-I T cells. While a weak cross-priming of CD8 + T cells was detected in WT mice, we observed a significantly augmented T cell cross-priming induced by both CD8α + DCs and CD11b + DCs in Ythdf1 −/− mice (Fig. 2f, Extended Data Fig. 3b ). In addition, we utilized a less sensitive model antigen SIY and confirmed that the enhanced cross-presentation capacity was consistently detected in Ythdf1 −/− DCs (Extended Data Fig. 3c ). To test whether crosspriming in DCs depends on RNA m 6 A methylation in general, we employed the CD11c-CreMettl14 f/f conditional knockout mice. We compared the cross-presentation capacity of Mettl14-deficient DCs and WT DCs. Indeed, DCs deficient in Mettl14 showed enhanced capacity in cross-presentation (Extended Data Fig. 3d ), confirming the critical role of the m 6 A-YTHDF1 axis in restricting the cross-priming capacity of DCs.
Considering the possibility that the increased cross-capacity of YTHDF1-deficient DCs for priming could be attributed to differential expression of co-stimulatory molecules 23 , we evaluated the expressions of CD80 and CD86 on DCs. WT and Ythdf1 −/− DCs expressed comparable levels of CD80 and CD86, and also exhibited a similar ability to directly prime OT-I T cells with peptide stimulation (Extended Data Fig. 3e, f) . In addition, loss of YTHDF1 did not affect the composition of DC subpopulations in naive mice (Extended Data Fig. 4 ), nor did it affect LPS-mediated DC activation (Extended Data Fig. 5a ). These findings suggest that loss of YTHDF1 increases cross-priming capacity of DCs, rather than impacting the development or activation of DCs.
To determine if YTHDF1 deficiency enhances the cross-presentation of tumor antigens on DCs, leading to better cross-priming of CD8 + T cells 24, 25 , we assessed the abundance of H-2K b -SIINFEKL complexes on DCs from WT and Ythdf1 −/− mice bearing B16-OVA tumors. Although phagocytosis of tumor cells was similar in WT and Ythdf1 −/− mice (Extended Data Fig. 5b, c) , H-2K b -SIINFEKL complexes were significantly higher in tumor-infiltrating Ythdf1 −/− DCs than in WT DCs (Fig. 2g, h) . Furthermore, compared with splenic WT DCs, DCs from Ythdf1 −/− mice exhibited a higher potential for crosspresentation of soluble OVA in vitro (Extended Data Fig. 5d ). These data suggest that DCs from Ythdf1 −/− mice possess improved antigen-presentation relative to DCs from WT mice.
To investigate whether the antitumor immunity relies on loss of Ythdf1 specifically in DCs, we generated chimeric, DC-specific Ythdf1 knockout mice. Specifically, we reconstituted irradiated mice with a 1:1 mixture of Ythdf1 −/− bone marrow cells and of WT bone marrow cells with a Zbtb46-DTR transgene, which drives expression of the diphtheria toxin receptor in classical DCs. Upon administration of diphtheria toxin (DT), WT cDCs expressing Zbtb46-DTR are selectively eliminated, with all remaining cDCs in Zbtb46-DTR:Ythdf1 −/− being Ythdf1-deficient. We also established chimeric Zbtb46-DTR:Ythdf1 +/+ mice as controls. We found that B16-OVA tumors grew similarly in Zbtb46-DTR:Ythdf1 +/+ and Zbtb46-DTR:Ythdf1 −/− chimeric mice that were not treated with DT (Fig. 2i) . Importantly, treatment with DT substantially reduced tumor growth in Zbtb46-DTR:Ythdf1 −/− mice compared to Zbtb46-DTR:Ythdf1 +/+ mice (Fig. 2i ). These data demonstrate that loss of Ythdf1 specifically in cDCs is sufficient to generate the antitumor response. Together, these findings suggest that YTHDF1 in cDCs limits their cross-presentation capacity in vivo, and that altered T cell or DC homeostasis or development in Ythdf1 −/− mice does not substantially contribute to the antitumor activity.
We next performed RIP-seq to map target transcripts bound by YTHDF1 in Flt3L-DCs. YTHDF1-binding sites were highly reproducible between two biological replicates (Extended Data Fig. 6a, b) , and were predominantly distributed in the coding region and 3' UTR (Extended Data Fig. 6c, d ). Given that YTHDF1 is known to affect mRNA translation 5 , we assessed the translational efficiency of WT and Ythdf1 −/− DCs by ribosome profiling. Antibody-based m 6 A profiling and RNA-seq were also performed in the same cells. We categorized transcripts into three groups: non-m 6 A marked transcripts, m 6 Acontaining transcripts, and m 6 A-marked transcripts bound by YTHDF1. As expected, we found a significant decrease of translation efficiency, particularly for YTHDF1-targeted and m 6 A-marked transcripts, in Ythdf1 −/− DCs compared to WT DCs (Fig. 3a, b) , while Ythdf1 deficiency did not substantially alter the distribution of m 6 A in mRNAs from DCs (Fig. 3c) .
To determine functional pathways associated with YTHDF1-targeted mRNAs, we analyzed m 6 A-marked mRNAs that are both targets of YTHDF1 and translationally regulated by YTHDF1. We performed Gene Ontology (GO) Enrichment Analysis, which showed that YTHDF1-targeted transcripts were enriched for functions in the KEGG pathways of phagosome and lysosome (Fig. 3d) . It is known that limiting lysosomal proteolysis in DCs could enhance the cross-presentation by minimizing destruction of internalized antigens 26, 27 . We noticed that translation of a group of transcripts encoding lysosomal cathepsins, which are responsible for antigen degradation in DC lysosomes 26, 27 , was repressed in Ythdf1 −/− DCs compared with WT control (Fig. 3e) . In contrast, the translational efficacy of co-stimulatory/inhibitory molecules (signal 2) and cytokines (signal 3) did not exhibit substantial change in YTHDF1-deficient Flt3L-DCs (Extended Data Fig.  6e ). In line with the observation in Flt3L-DCs, loss of Ythdf1 resulted in decreased translational efficiency of cathespins in GMCSF-induced bone marrow DCs (GMDCs) (Extended Data Fig. 7a-f) . Consistently, we found that multiple cathepsin transcripts are bound by YTHDF1, and Ythdf1 knock-out resulted in significant decreases of the translation efficiency of these genes, in both GMDCs and Flt3L-DCs (Extended Data Fig. 7g ). These data suggest lysosomal cathepsins as the main targets controlled by YTHDF1, which subsequently affect the cross-priming capacity of DCs.
Consistent with the reduced translational efficiency of m 6 A-marked transcripts in Ythdf1 −/− cDCs based on ribosome profiling, we also observed a downregulation of cathepsins from Ythdf1 −/− cDCs compared to WT cDCs in vivo (Fig. 4a ) and in vitro (Extended Data Fig.   8a ), although the decay of their transcripts was less affected (Extended Data Fig. 8b ). We reasoned that the reduced cathepsin levels may delay the degradation of the ingested neoantigens and facilitate a sustained antigen release within endosomes/lysosomes, thereby contributing to the improved antigen presentation in Ythdf1 −/− DCs. To test this hypothesis, we co-cultured GMDCs from WT and Ythdf1 −/− mice with B16-OVA cells overnight and assessed purified DCs for intact residual OVA. We observed more residual intact OVA in Ythdf1 −/− DCs compared to Ythdf1 +/+ GMDCs (Extended Data Fig. 8c ). We subsequently investigated whether the reduced translation efficiency of the YTHDF1 target cathepsins affects cross-presentation in Ythdf1 −/− DCs. Indeed, inhibition of cathepsins using a broadspectrum cysteine protease inhibitor E64 or more selective inhibitors CA-074 (for cathepsin B) and cathepsin L inhibitor III notably enhanced the efficiency of cross-priming in wildtype DCs (Extended Data Fig. 8d-f) . Moreover, the in vivo antitumor response was also markedly improved by cathepsin blockade (Fig. 4b, Extended Data Fig. 8g ), suggesting that cathepsins are critical factors determining the antitumor response in the current system. Collectively, these data show that loss of YTHDF1 in DCs attenuates antigen degradation by restricting the expression of lysosomal proteases, leading to improved cross-presentation and better cross-priming of CD8 + T cells.
Finally, we examined whether loss of YTHDF1, with increased neoantigen-specific CD8 + T cells, could enhance the antitumor response of immune checkpoint blockade, which targets the T cell inhibitor receptor PD1. Since Ythdf1 −/− mice showed a marked increase of IFNγ in CD8 + T cell and IFNγ signaling upregulates the expression of PD-L1 28 , the ligand for PD1, we evaluated the level of PD-L1 and observed increased PD-L1 expression in tumor cells from Ythdf1 −/− tumor-bearing mice (Fig. 4c) , whereas neutralizing IFNγ diminished the expression of PD-L1 (Extended Data Fig. 9 ). We then tested whether PD-L1 blockade can potentiate the antitumor response in Ythdf1 −/− mice. We treated WT and Ythdf1 −/− tumor-bearing mice with an anti-PD-L1 antibody (clone 10F.9G2). Although tumor regression occurred in 40% of untreated Ythdf1 −/− mice or anti-PD-L1-treated WT mice, we found that 100% of Ythdf1 −/− mice showed complete tumor regression after PD-L1 blockade (Fig. 4d) . These data suggest that combining a checkpoint blockade with YTHDF1 depletion could be a potential new therapeutic strategy to improve the outcome in patients with low response to checkpoint blockade.
In line with the observations in mouse models, we found that colon cancer patients with low expression of YTHDF1 in tumor stroma tended to have higher number of CD8 + cells, while biopsies with high expression of YTHDF1 in tumor stroma lacked CD8 + cell infiltrates ( Fig.  4e-f) , further supporting the notion that the reduced YTHDF1 expression may correlate with the T-cell inflamed tumor microenvironment.
Tumors can evade immune recognition despite expressing neoantigens. Our current results reveal that the m 6 A-marked mRNAs encoding lysosomal proteases are recognized by YTHDF1 in DCs. YTHDF1 binding promotes translation of lysosomal proteases, suppressing the cross-presentation of engulfed tumor neoantigens, which represents a previously unrecognized mechanism of immune evasion. Our data did not exclude potential contributions from other targets of YTHDF1; further investigation of complex regulatory pathways mediated by the m 6 A axis is necessary to expand current knowledge and uncover additional features of antitumor immunity discovered here. Finally, this work suggests that YTHDF1 could be a therapeutic target for immunotherapy in combination with emerging checkpoint inhibitors or DC vaccines.
METHODS

Mice
Ythdf1 −/− mice were generated as previously described 15 . Founder mice with mutant alleles were backcrossed to C57BL/6J for two generations. Mice used for experiments are further backcrossed to C57BL/6J for seven generations, totally 9 generations. To ensure the comparability in genetic background, mice were maintained by crossing heterozygous and heterozygous. Ythdf1 −/− mice or their littermates control WT mice were used in all experiments. Littermates were co-housing during experiments to reduce variants in their microbiome and environment. Primers used for genotyping of Ythdf1 −/− mice: CACCTGAGTTCAGATCATTAC and GCTCCAGACTGTTCATCC. Female Rag2 −/− mice, 2C CD8 + T cell receptor (TCR)-Tg, CD11c-Cre and Zbtb46-DTR mice were purchased from Jackson laboratory. Female CD11c-CreMettl14 f/f conditional knockout mice were generated in house. All mice were used at 6-12 weeks of age. All the mice were maintained under specific pathogen-free conditions and used in accordance with the animal experimental guidelines set by the Institute of Animal Care and Use Committee. This study has been approved by the Institutional Animal Care and Use Committee of The University of Chicago.
Cell lines
MC38 is a murine colon adenocarcinoma cell line that was provided by D. Bartlett (University of Pittsburgh, Pittsburgh). B16-OVA, an OVA-transfected clone derived from the murine melanoma cell line B16, were provided by Dr. Yang-Xin Fu (UT Southwestern).
B16F10 cell line was purchased from ATCC. MC38-zsGreen-OTIp (MC38-OZ) and B16F10-zsGreen-OTIp (B16-OZ) were selected for a single clone after being transduced by lentivirus expressing zsGreen-OTIp (SIINFEKEL). MC38-SIY is an EGFR-SIY-transfected clone derived from the murine colon cell line MC38. Cells were maintained either in DMEM (Invitrogen) supplemented with 10% FBS and 1% penicillin-streptomycin supplemented with 2 mM L-glutamine, 1 mM sodium pyruvate and 0.1 mM non-essential amino acid at 37 °C in 5% CO 2 .
Primary cell cultures
Single-cell suspensions of bone marrow cells were cultured in RPMI-1640 medium containing 10% fetal bovine serum, supplemented with 20 ng/ml GM-CSF (Biolegend). Fresh media with GM-CSF was added into culture on days 3 and 5. On day 6, CD11c + DCs were purified using EasySep Mouse CD11c Positive Selection Kit II (STEMCELL). To culture Flt3L-DCs, single-cell suspensions of bone marrow cells were cultured in IMDM medium containing 10% fetal bovine serum at the concentration of 1×10 6 /ml. Cells were supplemented with 100 ng/ml Flt3-Ligand (PEPROTECH) for 9-10 days to obtain the Flt3L-DCs. mice were inoculated with 1× 10 6 B16-OVA cells. On day 11, mice with established tumors were treated with E64 intratumorally. For anti-PDL1 treatment, 1× 10 6 B16-OVA tumor cells were s.c. injected into the flank of mice. Tumors were allowed to grow for seven days and treated i.p. by anti-PDL1 (clone10F.9G2) or Rat Ig. Tumor-free mice after treatment were monitored over time and the percentage of tumor-regression was calculated. To block IFNγ, tumor-bearing mice were treated with 50 μg anti-IFNγ m 6 Ab (clone XMG1.2) intratumorally and PD-L1 expression on tumor cells was evaluated by flow cytometry. All antibodies were 'InVivoMAb' from BioXCell. For adoptive transfer of T cells, Rag mice were inoculated with 5×10 5 B16-OVA on day 0. On the same day, T cells were purified from WT or Ythdf1 −/− mice using T cell negative isolation Kit (STEM CELL). 5×10 6 T cells were i.v. injected into Rag2 −/− mice. Tumor-bearing mice were sacrificed before the diameter of tumor reached to 2 cm and tumor size limit has been approved by the Institutional Animal Care and Use Committee of The University of Chicago.
Generation of bone marrow chimera
To generate bone marrow chimeric mice, C57BL/6 mice were exposed to 800 rads of X-ray. After 24 hours, 5×10 6 bone marrow cells, consisting of 2.5×10 6 WT or Ythdf1 −/− BM cells and 2.5×10 6 Zbtb46-DTR BM cells, were i.v. injected into irradiated mice. Six weeks after reconstitution, Zbtb46-DTR:Ythdf1 +/+ and Zbtb46-DTR:Ythdf1 −/− mixed BM chimera mice were inoculated with 10 6 B16-OVA cells and treated with 400 ng diphtheria toxin (sigma) or PBS every other day for sixteen days.
Flow cytometry and cell sorting
For flow cytometric analysis and cell sorting, tumors, lymph nodes and spleens were collected from mice and digested with 0.26 U/ml Liberase TM and 0.25 mg/ml DNase I at 37°C for 30 min. Samples were then filtered through a 70 μm cell strainer and washed twice with staining buffer. Cells were re-suspended in staining buffer (PBS with 2% FCS and 0.5 M EDTA). Cells were incubated with Fc Block (clone 2.4G2; BioX Cell) for 10 min. Subsequently, specific antibodies were added and staining was continued for 30 min on ice. Information for all the antibodies used are provided in Supplementary Table 1 . OT-I specific T cells were stained using iTAg Tetramer/H-2K b OVA (SIINFEKEL) (MBL). After a washing step, cells were either analyzed on a BD Fortessa (BD) or sorted by AriaIIIu (BD). For the staining of cathepsins, splenocytes were stained with CD11c, B220, MHCII, CD8 and CD11b and then fixed with 4% PFA (Biolegend) for 30 minutes. Fixed cells were then washed twice with the 1x intracellular staining perm and wash buffer (Biolegend). Antibody against CTSA, CTSB, CTSD or CTSH was added and incubated overnight respectively. Alexa Fluor 568 Goat-anti-Rabbit IgG was added as the secondary antibody. CD11c + MHCII + B220 − was gated and the expression of cathepsins was evaluated by the fluorescence intensity. Analysis of flow cytometry data was performed using Flowjo (Treestar).
Measurement of IFNγ-secreting CD8 + T cells by ELISPOT assay
For antigen-specific CD8 + T cell functional assay in the B16-OVA model, 12 days after tumor inoculation, 3×10 5 lymphocytes were re-stimulated with 1μg/ml SIINFEKEL or MC38 tumor cells (lymphocyte:MC38 = 50:1) for 48 hours. 96-well HTS-IP plate (Millipore) was pre-coated with anti-IFNγ antibody (BD Bioscience) with a 1:250 dilution overnight at 4 °C. After co-culture, cells were removed. 2 mg/ml biotinylated anti-IFNγ antibody (BD Bioscience) with a 1:250 dilution was added and incubated for 2 h at room temperature or overnight at 4°C. Avidin-horseradish peroxidase (BD Bioscience) with a 1:1000 dilution was then added and the plate was incubated for 1h at room temperature. The cytokine spots of IFN-γ were developed according to product protocol (BD Bioscience).
Antigen-presentation assay
For cross-presentation of tumor neoantigen, CD11b + or CD8 + DC were purified from draining lymph node of WT or Ythdf1 −/− mice six days after inoculating with B16-OVA, MC38-OTIp or MC38-EGFR-SIY. OT-I or 2C naive CD8 + T cells were isolated from lymph nodes and spleen of 6 to 12-week-old mice. Negative selection was carried out with a negative CD8 isolation kit (StemCell Technologies, Inc.) following manufacturer's instruction. DCs were co-cultured with OT-I naive CD8 T cells at the ratio of 1:10 for three days with or without 1 μg/ml SIINFEKEL peptide. For cross-presentation of soluble OVA, splenic DCs were sorted and stimulated with 100 ng/ml LPS overnight. DCs were then pulsed with different concentration of OVA (endotoxin free, Sigma) for 5 hours. Cells were washed and co-cultured with OT-I naive CD8 + T cells for three days. For in vitro crosspresentation of tumor neoantigen, Flt3L-DCs were collected on day 9-10 and co-cultured with necrotic B16-OVA tumor cells overnight. B220 − CD11c + cells were subsequently purified. GMDCs from Mettl14 f/f or CD11c-CreMettl14 f/f mice were harvested on day 6 and co-cultured with necrotic B16-OVA tumor cells for 16 hours. To inhibit cathepsins, GMDCs were pre-treated with E64 (sigma) for two hours followed by co-culturing with tumor cells. CD11c + cells were then purified and incubated with naive CD8 + T cells from OT-I mice for three days. IFN-γ production was detected by IFN-γ Flex Set CBA assay (BD Bioscience). To inhibit cathepsins in ex vivo cDCs, WT or Ythdf1 −/− mice were inoculated with 5×10 5 MC38. 36 hours after tumor inoculation, spleens were collected and digested, and CD11c + DCs were purified using EasySep Mouse CD11c Positive Selection Kit II (STEMCELL). CD11 + cDCs were then treated with 0.04 μM E64 (Sigma) overnight followed by coculturing with OVA protein for 4 hours. Any free OVA protein was then removed from the culture medium, and CD11c + cells were incubated with CTV-labelled OT-I cells for three days. The cross-priming capacity of DC was analyzed by the dilution of CTV in CD8 + T cells. For cathepsin inhibition assay in vitro, Flt3L-DCs were treated with 5μg/ml CA-074 methyl ester (Selleck), 5μg/ml cathepsin L inhibitor III(Sigma) or the combination (5μg/ml CA-074 methyl ester and 5μg/ml cathepsin L inhibitor III) for 2 h followed by co-culturing with necrotic B16-OVA for 16 h, and then Flt3L-DCs were purified using EasySep Mouse CD11c Positive Selection Kit II (STEMCELL). The purified cells were incubated with OT I cells at the ratio of 1:20 for three days. The cross-priming capacity of DCs was then evaluated by the IFN-γproduction. To detect the MHC-H2K b -SIINFEKEL, mice were inoculated with B16-OVA. After 12 days, tumors were collected and tumor infiltrating DCs (CD45 + CD11b + ly6c − MHCII + CD24 + CD11c + ) were stained with monoclonal antibody 25.D1.
Cell trace violet labelling
10 million splenocytes from naive OT-I mouse were re-suspended in 1 ml PBS followed by incubating with 5 uM CellTraceViolet Dye(CTV, ThermoFisher) at 37°C for 20 minutes. 5 ml RPMI-1640 medium was added to the cells and incubated for 5 minutes to remove the free dye in the solution. These cells were then centrifuged and incubated with pre-warmed RPMI-for at least 10 minutes at room temperature for subsequent analysis.
RIP-seq
20 million GMDCs were harvested and co-cultured with or without necrotic B16-OVA overnight. The procedure was adapted from the previous report 10 . Five million Flt3L-DCs were harvested. DCs were then purified and pelleted by centrifuge for 5 min. Cells were washed twice with cold PBS and the cell pellet was re-suspended with 2 volumes of lysis buffer (150 mM KCl, 10 mM HEPES pH 7.6, 2 mM EDTA, 0.5% NP-40, 0.5 mM DTT, 1:100 protease inhibitor cocktail, 400 U/mL RNase inhibitor). Lysate was incubated on ice for 5 min and centrifuged for 15 min to clear the lysate. 1/10 volume of cell lysate was saved as input and total RNA was extracted by Trizol. The rest of cell lysate was incubated with 5 μg anti-YTHDF1 (Proteintech) at 4°C overnight with gentle rotation followed by incubation with 40μl protein G beads for 1 hour at 4°C. The beads were then washed five times with 1 mL ice-cold washing buffer (200 mM NaCl, 50 mM HEPES pH 7.6, 2 mM EDTA, 0.05% NP-40, 0.5 mM DTT, 200 U/mL RNase inhibitor). The IP complex was resuspended in 400 μl 1xProteinase K and digested with 2 mg Proteinase K at 55°C for 1 hour. RNA was then extracted by RNA isolation kit (Zymo). Input and IP RNA of each sample were used to generate the library using TruSeq stranded mRNA sample preparation kit (Illumina).
m 6 A-seq
Total RNA was isolated from DCs. Polyadenylated RNA was further enriched from total RNA by using Dynabeads® mRNA Purification Kit (Invitrogen). RNA samples were fragmented into ~100-nucleotide-long fragments with sonication. Fragmented RNA (100 ng mRNA or 5 μg total RNA) was performed m 6 A-IP following EpiMark N 6 -methyladenosine enrichment kit (NEB E1610S) protocol. RNA was enriched through RNA Clean&Concentration-5 (Zymo Research) and used for library generation with SMARTer Stranded Total RNA-Seq Kit (Takara). Sequencing was performed at the University of Chicago Genomics Facility on an Illumina HiSeq4000 machine in single-read mode with 50 bp per read. Sequencing reads were aligned to the mouse genome mm9 by STAR (version 2.6.0c) 29 . The m 6 A-enriched regions (peaks) in each m 6 A-IP sample were detected by MACS2 (version 2.1.1.20160309) 30 with q value less than 0.01 and corresponding m 6 AInput sample was used as the control. Peaks that were detected by both replicates were considered as high confident peaks. The peaks annotation and binding motif were analyzed by HOMER (version 4.9) 31 .
Ribosome profiling
5×10 6 DCs were treated with 100 μg/ml cycloheximide (CHX) for 7 minutes. The cells were then harvested by the cell lifter. The cell suspension was spun at 400g for 5 min and the cell pellet was washed twice with 5 ml cold PBS with CHX (100 μg/ml). 200 μl lysis buffer (10 mM Tris, pH 7.4, 150 mM KCl, 5 mM MgCl 2 , 100 μg/ml CHX, 0.5% Triton-X-100, freshly added 1:100 protease inhibitor, 40 U/ml SUPERasin) was added to the cell pellet and lysed on ice for 15 minutes with rotating. 10% clarified lysate was saved as INPUT and the rest lysate was separated through a 5 ml 10%−50% sucrose gradient and centrifuged at 4 °C for 2 h at 28,000 r.p.m. Fractions were collected separately and analyzed by Qubit™ RNA HS Assay Kit (Invitrogen). The fractions corresponding to monosome or polysome were combined resepectively and concentrated on Amicon-Ultra 100K columns (Millipore). Two A260 units of ribosome fractions were digested with 60 U RNase I (Ambion) at room temperature for 30 minutes. RNA was extracted by RNA Clean&Concentrate (Zymo) and ribosomal RNA were deleted prior to size selection. RNA fragments (26-32 nt) were isolated by 15% denaturing Urea-PAGE gel. RNA was eluted from gel in elution buffer (300 mM sodium acetate pH 5.2, 1 mM EDTA) followed by phenol-chloroform extract and ethanol precipitation. RNA fragments were dephosphorylated and prepared into libraries by SMARTer® smRNA-Seq Kit (Clontech). The first 3 bases of sequencing reads were removed fastx_trimmer (version 0.0.14). The adapter sequences and polyA tails were firstly trimmed from sequencing reads by using cutadapt (version 1.15) with --minimum-length 18 -n 3 -a "AAAAAAAAAAAAAA" -a "AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC" parameters 32 . Trimmed reads were filtered for mitochondrial DNA and ribosomal RNA by Bowtie2 (version 2.3.4) 33 . All remaining reads were mapped to the mouse genome mm9 with STAR (version 2.6.0c) 29 . Uniquely mapped reads were selected by using SAMtools (version 1.7) 34 with mapping quality >= 20, and then removing duplication. The raw counts of coding regions were calculated by HOMER (version 4.9) 31 . The differentially TE (translational efficiency 35 
Measurement of RNA lifetime
DCs were seeded in 24-well plate at 50% confluency. After 2 h, actinomycin D was added to 5 mg/ml at 3 h, 1 h and 0 h before collection. The total RNA was purified by RNeasy kit with an additional DNase-I digestion step on column. RNA quantities were determined by RT-qPCR. The specific primers used are as follows: Ctsb_Forward: CTGCTTACCATACACCAT, Ctsb_Reverse: TCCTTCACACTGTTAGAC; Ctsd_Forward: GGCAAGAGGTATCAAGGT, Ctsd_Reverse: CAGGTAGAAGGAGAAGATGT; Ctsl_Forward: GAGTTCGCTGTGGCTAAT, Ctsl_Reverse: GAGGTTCTTGCTGCTACA; Gapdh_Forward: ACCTGCCAAGTATGATGA, Gapdh_Reverse:
GGAGTTGCTGTTGAAGTC.
Immunohistochemistry of human biopsies
All samples encompassing tumor biopsies from 22 colorectal cancer patients were obtained with informed consent under a protocol approved by the University of Chicago Institutional Review Board. We have complied with all relevant ethical regulations. Information about the patient sex, age, and tumor characteristics are given in Supplementary Table 2 . To stain YTHDF1 and CD8, antigen retrieval was performed with 10 mM Tris base, 1 mM EDTA, 0.05% Tween 20, pH9. Slides were processed with the VECTASTAIN Elite ABC HRP kit and DAB Substrate Kit (Vector Laboratories). Slides were counterstained with hematoxylin and dehydrated through graded alcohols and xylene. A total of 22 tumor samples had sufficient tissue for unambiguous analyses; For IHC quantification, DAB stains of IHC images were separated by color deconvolution algorithms47 in Fiji, a derivative of ImageJ. The mean DAB intensity of 3 random images at 795×650 pixels was calculated and converted into optical density (OD). CD8 positive cells were analyzed by Image J cell counter. The average infiltration of CD8 + cell and average expression of YTHDF1 were assessed within the surrounding stroma tissues.
Western blot analysis
To detect the expression of cathepins, GMDCs were harvested on day 6 and co-cultured with necrotic B16-OVA cells at the ratio of 1:1 for 16 hours. CD11c + DCs were then purified. Equal numbers of cells were lysed on ice for 15 min using 1xlysis buffer (CST) supplemented with a protease inhibitor cocktail (Calbiochem). Cell lysis was centrifuged at 16,100g at 4°C for 15 min. Clarified supernatant was loaded into 4-12% NuPAGE Bis-Tris gel and transferred to PVDF membranes (Life Technologies). Membranes were blocked for 1 hour in 5% milk TBST and then incubated with primary antibodies in the blocking buffer overnight at 4°C. After 5 times washing, membranes were incubated with secondary antibodies for 1 hour at room temperature. The information for all the antibodies used are provided in Supplementary Table 1 .
Degranulation of tumor infiltrating NK cells
Tumor infiltrating leukocytes were resuspended at 5×10 5 /ml and stimulated with phorbol-12-myristate-13-acetate (PMA) (2.5 μg/ml) and ionomycin (0.5 μg/ml) in 96-well plate. CD107α-PE antibody and 1xbredeldin A (Biolegend) were added directly to the well and incubated for 4 h at 37 °C in 5% CO 2 . Cells were stained for CD45 and NK1.1 (BD Biosciences) for 30 min. Samples were washed and then fixed in 1% paraformaldehyde.
Phagocytosis in vivo
5 × 10 5 B16F10 cells expressing zsGreen-OTI were injected s.c. into WT and Ythdf1 −/− mice. Tumor tissues were harvested and digested.
Maturation of DC
GMDCs were harvested and co-cultured with 100 ng/ml LPS overnight. The cytokine production was measured by mouse inflammation kit (BD).
Identification of off-target site and T7EI assay
Identified two off-target loci for each sgRNA site with highest score were selectively amplified by primers listed below: mouse) and 510 bp fragment (for WT mouse) were carried out in 30 μl reaction, using 15 μl of 2x EasyTaq PCR SuperMix (AS111 TransGen Biotech), 0.75 μM each of forward and reverse primers and 1 μl genomic DNA. The reaction products were subjected to 1.5% agarose gel electrophoresis. For T7E1 cleavage assay, equal volume PCR products of Ythdf1 −/− and WT mouse were mixed and then denatured and annealed in NEBuffer 2
(NEB) using a thermal cycler. Hybridized PCR products were digested with T7 endonuclease I (NEB, M0302L) or ddH2O (as control) for 20 minutes at 37°C and subjected to 1.5% agarose gel electrophoresis.
Statistical analysis and reproducibility
No statistical method was used to predetermine sample size. Mice were assigned at random to treatment groups for all mouse studies and, where possible, mixed among cages. There were no mice excluded from experiments. Blinded staining and blinded analysis were performed for IHC experiments. Experiments were independently repeated two to three times. Data were analyzed using Prism 5.0 software (GraphPad) and presented as mean values ± s.e.m. The P values were assessed using one-tailed or two-tailed unpaired Student's t-test. For survival curve, statistics were done with the log-rank (Mantel-Cox) test. For translational efficiency, P values were calculated by likelihood ratio test and adjusted by Benjamini & Hochberg method. For cumulative distribution, two-sided KolmogorovSmirnov test was used to calculate the P values.
Data processing and analysis
Illumina reads were post-processed and aligned to the mouse mm9 assembly using STAR 29 program (version 2.6.0c) with default parameters. To visualize sequencing signals in the genome browser, we generated RIP-seq and m 6 A-seq bigwig files with bamCoverage function from deepTools (version 3.0.1) 37 with '-bs=1 --normalizeUsing BPM'. For RIPseq, Piranha software (version 1.2.1) 38 was to detect the binding sites of YTHDF1 with "-b 100 -i 100". Metagene plots were performed by the Bioconductor GUITAR 39 package (version 1.16.0). Peaks that were detected by both replicates were considered as high confident peaks. GO term analyses were performed by metascape 40 .
Data availability
The data that support the findings of this study are available from the corresponding author upon reasonable request. RIP-seq, Ribo-seq and m 6 A-seq data sets have been deposited in Gene Expression Omnibus under the accession number GSE115106. A summary of sequencing experiments is provided in Supplementary DCs were treated with Actinomycin D, RNAs collected at different time points after treatment, and mRNA levels were measured using RT-qPCR and represented as mRNA remaining after transcription inhibition (TI). ns not significant. c, GMDCs were co-cultured with necrotic B16-OVA cells overnight and OVA degradation in BMDCs was measure by Immunoblot. d, Ex vivo purified wild-type cDCs were pre-treated with 0.04 μM cathepsin inhibitor E64 and pulsed with OVA protein for 4 h. The cross-priming capacity of DCs was compared by co-culturing DCs with cell trace violet (CTV) labeled OTI-T cells. The proliferation was measured by the dilution of CTV. e, GMDCs were pre-treated with 0.2-2 μM cathepsin inhibitor E64 and co-cultured with B16-OVA cells. The cross-priming capacity of DC was compared by co-culturing DCs with isolated CD8 + T cells from naive OTI mice and analyzed by IFN-γ cytometric bead array. f, Flt3L-DCs were pre-treated with cathepsin inhibitor CA-074 or/and cathepsin L inhibitor III (CASIII), followed by coculturing with necrotic B16-OVA cells. Synergistic inhibition effects were observed. The cross-priming capacity of DC was determined. g, data points for Fig. 4b . n = 3 independent experiments with similar results (a, c); n = 2 independent experiments (b). n, numbers of sample size. Data are mean ± s.e.m. and were analyzed by two-tailed unpaired Student's ttest (e) or one-tailed unpaired Student's t-test (f). , c) ; one of three representative images per tumor was shown (e). n, numbers of mice. Data are mean ± s.e.m. and were analyzed by two-tailed unpaired Student's t-test (b, f) or two-tailed log-rank (Mantel-Cox) test (d).
